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**Abstract**

The neurobiological substrates underlying the transition from normal aging and mild cognitive impairment (MCI) to Alzheimer's disease (AD) are poorly understood, as are the mechanisms underlying the role of late-life depression (LLD) that is associated with increased risk of cognitive decline. AD pathology is associated with cognitive impairment and functional decline in both MCI and LLD. Substantial advances in neuroimaging instrumentation and radiotracer chemistry have enhanced the ability to study in vivo an increasing number of neurotransmitters, neuromodulators, and, importantly, neuropathological processes. This is an unprecedented opportunity to understand the neurobiology of early stage AD by testing mechanistic hypotheses derived from human post-mortem data and transgenic amyloid mouse models in the living human brain in the preclinical stages of AD. An understanding of the neurobiology of the early course of AD and of clinical progression is critically needed to identify individuals at risk, as well as to identify therapeutic targets for prevention and treatment. Several lines of evidence strongly support the investigation of serotonin degeneration associated with beta-amyloid deposition (Aβ). Transgenic amyloid mouse models show selective vulnerability of cortical monoamine projections, serotonin to a greater extent, in contrast to modest cortical and hippocampal neuronal loss. The pattern of MA degeneration in the mice is remarkably similar to MA pathology in Alzheimer's disease (AD) and parallels the course of cognitive deficits in the mice. Serotonergic deficits are a consistent finding in AD and in recent neuroimaging studies in LLD and MCI. Multi-modality molecular imaging methods were employed to test these observations from the mouse models in patients with LLD, MCI and normal controls.

MCI, LLD and demographically matched normal controls underwent clinical and cognitive evaluations, magnetic resonance imaging and high resolution positron emission tomography (HRRT) with well-established radiotracers for the serotonin transporter (SERT; \[^11^C\]-DASB), AβD (\[^11^C\]-PiB) and regional cerebral blood flow \[(rCBF; \[^15^O\]-water), respectively\]. SERT binding was correlated with cognitive measures (verbal and visuospatial memory).

Reduced 5-HTT was observed in MCI and LLD compared to controls in cortical and limbic areas affected by AD pathology, as well as sensory and motor areas, striatum and thalamus that are typically spared. The reduction in 5-HTT was greater and more extensive than grey matter atrophy or reduced rCBF in both groups compared to controls. Lower cortical SERT was associated with worse performance in tests of verbal and visuospatial memory, to a greater extent in MCI than controls.

The decrease of SERT in MCI and LLD observed in the present study, suggests that the serotonin system may represent a target for prevention and treatment, particularly the post-synaptic receptors (5-HT4 agonists, 5-HT6 antagonists) that may not be as severely affected as SERT. Studies are in progress to determine whether serotonin degeneration may be involved in the MCI to dementia transition and whether serotonin degeneration is related to other aspects of AD neuropathology.
